紫杉醇联合顺铂与紫杉醇单药治疗非小细胞肺癌的疗效比较

Paclitaxol combined with cisplatin in treatment for non-small cell lung cancer

目的:观察紫杉醇联合顺铂与紫杉醇单药治疗非小细胞肺癌(NSCLC)的疗效及不良反应。方法:采用前瞻性随机对照研究方法,对49例非小细胞肺癌初治患者进行随机分组。TAX组22例采用TAX单药治疗方案,TAX175mg/m2,第1天,每4周重复;TP组27例,DDP30mg/m2,第1-3天,TAX75mg/m2,第1天,每4周重复。结果:TP组与TAX组总有效率分别为48.1%与43.3%(P=0.716);疾病控制率分别为88.8%和86.7%(P=0.799)。TP组白细胞下降比TAX组稍低,在不良反应方面TP组比TAX组略有改善。结论:DDP联合TAX是治疗NSCLC的有效方案。可取得与TAX相似的有效率。在某些不良反应方面显示出一定优势。

Objective：To investigate the therapeutic effect and side effect on NSCLC patients treated with cisplatin combined with paclitaxol and paclitaxolalone.Methods：Forty nine NSCLC patients were randomized into two groups.TP group：cisplatin 30mg/m2,d1-3,paclitaxol 75mg/m2,d1,repeated every 4 weeks.TAX group：Paclitaxol 175mg/m2,d1,repeated every 4 weeks.Results：The overall response rate were 48.1%vs 43.3%（P=0.716）;and the disease control rate were 88.8% vs 86.7%（P=0.799）in TP and TAX groups.Side reactions of TP group were less than TAX group.Conclsion：Cisplatin combined with paclitaxol is an effective treatment regimen for NSCLC patients compared with regimen with paclitaxol the response rate was similar.Cisplatin regimen shows superiority in side effect.